Active substance
Oral rehydration salts
- SFDA 4
- WHO EML 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HYDROLYTE ORAL REHYDRATION SOLUTION | Solution · Oral use | 1 Bottle | SAR 7.00 | Generic · OTC | SAUDI PHARMACEUTICAL INDUSTRIES | Valid | |
| AQUASAL SACHETS | Powder for oral solution · Oral use | 9 Sachet | SAR 4.85 | NCE · OTC | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed | |
| ORASOL POWDER | Powder for oral solution · Oral use | 10 Sachet | SAR 7.75 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed | |
| REHYDRAN- N | Powder for oral solution · Oral use | 10 Sachet | SAR 1.50 | Generic · OTC | CHEMICAL INDUSTRIES DEVELOPMENT (CID) | Suspended · Not Marketed |
Indications — CHI Daman Drug Formulary
BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - VIBRIO CHOLERAE; DIARRHEA; TRAVELLER'S DIARRHEA; VIRAL GASTROENTERITIS
WHO WHO Model List of Essential Medicines (2025)
- 26.1. Solutions correcting water, electrolyte and acid-base disturbances > Oral · core
Other specified disorders of fluid, electrolyte or acid-base balance
Powder for dilution in 200 mL, 500 mL, 1 L: - glucose 75 mEq or mmol/L - sodium 75 mEq or mmol/L - chloride 65 mEq or mmol/L - potassium 20 mEq or mmol/L - citrate 10 mEq or mmol/L - osmolarity 245 mOsm/L - glucose 13.5 g/L - sodium chloride 2.6 g/L - potassium chloride 1.5 g/L - trisodium citrate dihydrate 2.9 g/L - 17.5.1. Oral rehydration · core
Diarrhoea
Powder for dilution in 200 mL, 500 mL, 1 L: - glucose 75 mEq or mmol/L - sodium 75 mEq or mmol/L - chloride 65 mEq or mmol/L - potassium 20 mEq or mmol/L - citrate 10 mEq or mmol/L - osmolarity 245 mOsm/L - glucose 13.5 g/L - sodium chloride 2.6 g/L - potassium chloride 1.5 g/L - trisodium citrate dihydrate 2.9 g/L
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.